Antunes, LilianaMazagatos, ClaraMartínez‐Baz, IvánNaesens, ReinoutBorg, Maria‐LouisePetrović, GorankaFatukasi, TerraJancoriene, LigitaMachado, AusendaOroszi, BeatrixHusa, PetrLazar, MihaelaDürrwald, RalfHoward, JenniferMelo, ArysePérez‐Gimeno, GloriaCastilla, JesúsBernaert, EvaDžiugytė, AušraMakarić, Zvjezdana LovrićFitzgerald, MargaretMickienė, AuksėGómez, VerónicaTúri, GergőSoučková, LenkaMarin, AlexandruTolksdorf, KristinNicolay, NathalieRose, Angela M.C.European Hospital Vaccine Effectiveness Group2025-03-062025-03-062024-08-15Influenza Other Respir Viruses. 2024 Aug;18(8):e13360. doi: 10.1111/irv.13360.1750-2640http://hdl.handle.net/10400.18/10418We conducted a multicentre test-negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14–29days and 40% at 60–105days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5months post vaccination, with VE>70% in older adults (≥65 years) up to 1month post vaccination.engCOVID-19 XBB.1.5SARS‐CoV‐2 HospitalisationVaccineVaccine EffectivenessEuropeEstados de Saúde e de DoençaInvestigação em Serviços de SaúdeInfecções Respiratóriasjournal article10.1111/irv.13360